Maxim Group analyst Michael Okunewitch maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report) yesterday. The company’s shares closed yesterday at $0.74.
According to TipRanks, Okunewitch is an analyst with an average return of -29.0% and a 23.66% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Lexaria Bioscience, Gilead Sciences, and Mediwound.
Currently, the analyst consensus on Kiora Pharmaceuticals is a Moderate Buy with an average price target of $3.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $8.52 and a one-year low of $0.46. Currently, Kiora Pharmaceuticals has an average volume of 1.52M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kiora Pharmaceuticals (KPRX) Company Description:
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
Read More on KPRX:
